Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002193778 | SCV002490629 | likely benign | Progressive myoclonic epilepsy type 9; Lipodystrophy, partial, acquired, susceptibility to | 2024-11-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004047111 | SCV003881875 | uncertain significance | not specified | 2023-03-01 | criteria provided, single submitter | clinical testing | The c.1792T>C (p.Y598H) alteration is located in exon 12 (coding exon 12) of the LMNB2 gene. This alteration results from a T to C substitution at nucleotide position 1792, causing the tyrosine (Y) at amino acid position 598 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |